aurora kinase A pseudogene 2Genealiases: AURKAPS2 · STK6LP
Q-omics provides the consensus-scored AURKAP2 profile across patient tissues and cancer cell-line models. AURKAP2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AURKAP2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, AURKAP2 RNA expression shows 8,187 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight ACC, COAD, and OV as cancer lineages where AURKAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AURKAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AURKAP2 survival associations across molecular data types. AURKAP2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AURKAP2 RNA expression–survival associations across cancer types. High AURKAP2 expression shows unfavorable associations in ACC, MESO, KIRC, LIHC and SKCM, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AURKAP2 RNA expression.
This table summarizes AURKAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for AURKAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AURKAP2 shows higher tumor expression in COAD, READ, STAD, PRAD, BRCA and HNSC. The COAD box plot shows higher AURKAP2 RNA expression in tumor versus normal tissue (log2 FC = +0.143, t-test p = .006).
This table shows molecular features associated with AURKAP2 in patient tissues and cancer cell lines. In patient samples, AURKAP2 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
